Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study.

Hansen TB, Brixen K, Vahl N, Jørgensen JO, Christiansen JS, Mosekilde L, Hagen C

The Journal of clinical endocrinology and metabolism1 Sept 1996Cited by 78 (Europe PMC)

PMID8784096DOI10.1210/jcem.81.9.8784096PepBankPUB-08784096

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

01HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, serum IGF-I increased by 263 +/- 98% during GH treatment (P < 0.001).
In plain wordsIn GH-deficient patients, serum IGF-I increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum IGF-I
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Measurements
IGF-I increase
263%
GH treatment
Source sentences
Summary
During GH treatment, serum insulin-like growth factor I increased 263 +/- 98% (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409601
02HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, serum osteocalcin increased by 376 +/- 78% during GH treatment (P < 0.005).
In plain wordsIn GH-deficient patients, serum osteocalcin increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum osteocalcin
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Measurements
Osteocalcin increase
376%
GH treatment
Source sentences
Summary
Serum osteocalcin, bone a alkaline phosphatase, and procollagen type I C-terminal propeptide increased by 376 +/- 78% (P < 0.005), 128 +/- 17% (P < 0.005), and 100 +/- 17% (P < 0.005), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409602
03HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, serum bone alkaline phosphatase increased by 128 +/- 17% during GH treatment (P < 0.005).
In plain wordsIn GH-deficient patients, serum bone alkaline phosphatase increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum bone alkaline phosphatase
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Measurements
Bone alkaline phosphatase increase
128%
GH treatment
Source sentences
Summary
Serum osteocalcin, bone a alkaline phosphatase, and procollagen type I C-terminal propeptide increased by 376 +/- 78% (P < 0.005), 128 +/- 17% (P < 0.005), and 100 +/- 17% (P < 0.005), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409603
04HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, serum procollagen type I C-terminal propeptide increased by 100 +/- 17% with GH (P < 0.005).
In plain wordsIn GH-deficient patients, serum procollagen type I C-terminal propeptide increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum procollagen type I C-terminal propeptide
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Measurements
Procollagen type I C-terminal propeptide increase
100%
GH treatment
Source sentences
Summary
Serum osteocalcin, bone a alkaline phosphatase, and procollagen type I C-terminal propeptide increased by 376 +/- 78% (P < 0.005), 128 +/- 17% (P < 0.005), and 100 +/- 17% (P < 0.005), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409604
05HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, serum type I collagen telopeptide increased by 158 +/- 39% during GH treatment (P < 0.005).
In plain wordsIn GH-deficient patients, serum type I collagen telopeptide increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum type I collagen telopeptide
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Measurements
Type I collagen telopeptide increase
158%
GH treatment
Source sentences
Summary
Serum type I collagen telopeptide and urinary levels of pyridinoline, deoxypyridinoline, and hydroxyproline rose by 158 +/- 39% (P < 0.005), 170 +/- 48% (P < 0.005), 156 +/- 78% (P < 0.005), and 161 +/- 50% (P < 0.005), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409605
06HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, urinary pyridinoline increased by 170 +/- 48% during GH treatment (P < 0.005).
In plain wordsIn GH-deficient patients, urinary pyridinoline increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseUrinary pyridinoline
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Measurements
Urinary pyridinoline increase
170%
GH treatment
Source sentences
Summary
Serum type I collagen telopeptide and urinary levels of pyridinoline, deoxypyridinoline, and hydroxyproline rose by 158 +/- 39% (P < 0.005), 170 +/- 48% (P < 0.005), 156 +/- 78% (P < 0.005), and 161 +/- 50% (P < 0.005), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409606
07HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, urinary deoxypyridinoline increased by 156 +/- 78% during GH treatment (P < 0.005).
In plain wordsIn GH-deficient patients, urinary deoxypyridinoline increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseUrinary deoxypyridinoline
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Measurements
Urinary deoxypyridinoline increase
156%
GH treatment
Source sentences
Summary
Serum type I collagen telopeptide and urinary levels of pyridinoline, deoxypyridinoline, and hydroxyproline rose by 158 +/- 39% (P < 0.005), 170 +/- 48% (P < 0.005), 156 +/- 78% (P < 0.005), and 161 +/- 50% (P < 0.005), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409607
08HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, urinary hydroxyproline increased by 161 +/- 50% during GH treatment (P < 0.005).
In plain wordsIn GH-deficient patients, urinary hydroxyproline increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseUrinary hydroxyproline
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Measurements
Urinary hydroxyproline increase
161%
GH treatment
Source sentences
Summary
Serum type I collagen telopeptide and urinary levels of pyridinoline, deoxypyridinoline, and hydroxyproline rose by 158 +/- 39% (P < 0.005), 170 +/- 48% (P < 0.005), 156 +/- 78% (P < 0.005), and 161 +/- 50% (P < 0.005), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409608
09HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, serum ionized calcium increased by 1.7 +/- 0.6% during GH treatment (P < 0.05).
In plain wordsIn GH-deficient patients, serum ionized calcium increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum ionized calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Measurements
Ionized calcium increase
1.7%
GH treatment
Source sentences
Summary
Serum ionized calcium rose by 1.7 +/- 0.6% (P < 0.05), whereas serum PTH decreased insignificantly.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409609
10HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, serum PTH decreased nonsignificantly during GH treatment.
In plain wordsIn GH-deficient patients, serum PTH did not change significantly during GH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeSerum PTH
Study
n: not reported in source
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Source sentences
Summary
Serum ionized calcium rose by 1.7 +/- 0.6% (P < 0.05), whereas serum PTH decreased insignificantly.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409610
11HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, vitamin D metabolites remained unaltered during GH treatment.
In plain wordsIn GH-deficient patients, vitamin D metabolites did not change during GH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeVitamin D metabolites
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Source sentences
Summary
Vitamin D metabolites remained unaltered.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409611
12HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, urinary calcium/creatinine increased transiently during GH treatment and returned to baseline at 9 months.
In plain wordsIn GH-deficient patients, urinary calcium/creatinine rose temporarily with GH and returned to baseline at 9 months.
Peptide
HGH (somatotropin)
Outcome
MixedUrinary calcium/creatinine
Study
n: not reported in source
Outcome group
Bone and joint · Kidney and urinary
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Source sentences
Summary
Urinary calcium/creatinine increased and phosphate/creatinine decreased transiently, returning to baseline values at 9 months.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409612
13HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, urinary phosphate/creatinine decreased transiently during GH treatment and returned to baseline at 9 months.
In plain wordsIn GH-deficient patients, urinary phosphate/creatinine fell temporarily with GH and returned to baseline at 9 months.
Peptide
HGH (somatotropin)
Outcome
MixedUrinary phosphate/creatinine
Study
n: not reported in source
Outcome group
Bone and joint · Kidney and urinary
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Source sentences
Summary
Urinary calcium/creatinine increased and phosphate/creatinine decreased transiently, returning to baseline values at 9 months.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409613
14HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, whole-body bone mineral density decreased by 2.4 +/- 0.6% during GH treatment (P < 0.05).
In plain wordsIn GH-deficient patients, whole-body bone mineral density decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseWhole-body bone mineral density
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Measurements
Whole-body BMD decrease
2.4%
GH treatment
Source sentences
Summary
When measured by dual energy x-ray absorptiometry, whole body bone mineral density (BMD) and (BMD) of the radius decreased 2.4 +/- 0.6% (P < 0.05) and 3.5 +/- 1.0% (P < 0.005), respectively, whereas no significant changes were observed in BMD of the femur or spine.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409614
15HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, radius bone mineral density decreased by 3.5 +/- 1.0% during GH treatment (P < 0.005).
In plain wordsIn GH-deficient patients, radius bone mineral density decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseRadius bone mineral density
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Measurements
Radius BMD decrease
3.5%
GH treatment
Source sentences
Summary
When measured by dual energy x-ray absorptiometry, whole body bone mineral density (BMD) and (BMD) of the radius decreased 2.4 +/- 0.6% (P < 0.05) and 3.5 +/- 1.0% (P < 0.005), respectively, whereas no significant changes were observed in BMD of the femur or spine.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409615
16HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, femur bone mineral density did not change significantly during GH treatment.
In plain wordsIn GH-deficient patients, femur bone mineral density did not change significantly during GH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeFemur bone mineral density
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Source sentences
Summary
When measured by dual energy x-ray absorptiometry, whole body bone mineral density (BMD) and (BMD) of the radius decreased 2.4 +/- 0.6% (P < 0.05) and 3.5 +/- 1.0% (P < 0.005), respectively, whereas no significant changes were observed in BMD of the femur or spine.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409616
17HumanNon-randomized trialEfficacy outcome
In GH-deficient patients, spine bone mineral density did not change significantly during GH treatment.
In plain wordsIn GH-deficient patients, spine bone mineral density did not change significantly during GH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeSpine bone mineral density
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
2 IU/m2 day · sc injections · 12 monthsAs given in this study (human).
Source sentences
Summary
When measured by dual energy x-ray absorptiometry, whole body bone mineral density (BMD) and (BMD) of the radius decreased 2.4 +/- 0.6% (P < 0.05) and 3.5 +/- 1.0% (P < 0.005), respectively, whereas no significant changes were observed in BMD of the femur or spine.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of GH substitution on skeletal mass, bone turnover, and calcium metabolism were investigated in 29 patients with GH deficiency who were randomized to sc injections with GH (2 IU/m2 day) or placebo for 12 months.
Report a problemFND-0878409617

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.